Abstract
Objective: Ebola Virus Disease (EVD), a deadly viral disease caused by the virus of filoviridae family is one of the worst recent outbreaks with the fatality rate of 90%. There are four different types of Ebola Virus includes Sudan (SUDV) Bundibugyo (BDBV), Tai Forest (TAFV), Reston (RESTV). Main host of the Ebola virus is the Pteropodidae family which includes fruit bats. It is transmitted through the close contact with blood, serum and other bodily fluids of different infected animals. Expression of symptoms occurs in 2 to 21 days. It majorly targets the immune system of the host through dendritic and macrophage cells and turns the body defense against itself resulting in the causation of infection. Its major symptoms are hemorrhagic fever and MODS (multiple organ dysfunctions). Other general symptoms include fever, fatigue, diarrhea, headache and abdominal pain. In an attempt to fight this pandemic and make a novel drug this study is a subsequent contribution. Outcome: Currently, there is no effective treatment of Ebola virus that has been proven. Using drug repurposing screens we have found 18 approved drugs that block Ebola virus like particles (VLP) entry in assay. Conclusion: Some active compounds at an IC50<10μM are identified. Each drug with a different target protein is still being tested. We can use these drugs for Ligand Based pharmacophore designing and further computational studies in order to identify the lead compound of the Ebola Virus. This lead compound could then be used for further optimization studies.
